LLC355 |
Katalog-Nr.GC81898
One-Click Copy Product Info
|
LLC355 is a discoidin domain receptor 1 ( DDR1 ) ATTEC degrader with a DC50 of 150.8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, Compound LLC355 (0.3-10000 nM; 1-24 h) dose- and time-dependently degrades DDR1 protein in NCI-H23 cells with a DC50 of 150.8 nM, without altering DDR2 levels[1]. Compound LLC355 (0.3 μM; 24 h) potently inhibits migration and invasion of NCI-H23 cells and reduces N-cadherin expression[1]. Compound LLC355 (0.1-1 μM; 10 days) potently suppresses colony formation of NCI-H23 cells over 10 days, with greater potency than DDR1 inhibitor 1[1]. Compound LLC355 (100-1000 nM; 24 h) does not induce apoptosis in NCI-H23 cells at 0.3 μM after 24 h treatment, but induces apoptosis at 1 μM[1].
References:
[1]. Liu L, et al. Discovery of as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1. Journal of medicinal chemistry. 2024 May 23;67(10):8043-8059.
| Cas No. | SDF | ||
| Chemical Name | (R)-N-(3-((4-(2-(2-((3-(N-(1-(3-Benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl )-4-methylbenzamido)propyl)amino)-2-oxoethoxy)ethyl)piperazin-1-yl)methyl)-5-(trifluorometh yl)phenyl)-4-ethyl-3-(pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzamide | ||
| Formula | C63H64ClF3N10O5 | M.Wt | 1133.69 |
| Löslichkeit | DMSO: 100 mg/mL (88.21 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 882.1 μL | 4.4104 mL | 8.8208 mL |
| 5 mM | 176.4 μL | 882.1 μL | 1.7642 mL |
| 10 mM | 88.2 μL | 441 μL | 882.1 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)